Biomarin Pharmaceutical (BMRN) EV to EBITDA (2010 - 2026)
Biomarin Pharmaceutical's EV to EBITDA was 33.75 in Q2 2026, up 217.9% from 10.62 a year earlier and up 51.0% from the prior quarter.
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) EV to EBITDA (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Biomarin Pharmaceutical's EV to EBITDA was 16.34 through Jun 30, 2026, up 142.9% year-over-year; for FY2025, it came in at 20.18, up 2.8% from FY2024.
- In earlier years, EV to EBITDA was 19.64 in FY2024 (-66.7%), 58.97 in FY2023 (-13.8%), 68.39 in FY2022 (-88.5%) and 592.84 in FY2021 (+146.1%).
- The Q2 2026 figure marks the highest quarterly EV to EBITDA since Q2 2024.
- Compared with a year earlier, EV to EBITDA has increased for three straight quarters, with an average decline of 8.0% over the last eight quarters.
- The best year-over-year quarter for EV to EBITDA over five years was Q2 2026 (growth of 217.9%); the worst was Q4 2022 (a decline of 88.5%).
- Per Business Quant data, BMRN's EV to EBITDA in the three quarters before Q2 2026 was 22.35 (Q1 2026), 20.18 (Q4 2025) and 12.78 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | Biomarin Pharmaceutical | 10.64 Bn | 4.51 Bn | 786.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.89 |
| Mar 31, 2026 | 21.93 |
| Dec 31, 2025 | 20.10 |
| Sep 30, 2025 | 12.75 |
| Jun 30, 2025 | 10.59 |
| Mar 31, 2025 | 17.21 |
| Dec 31, 2024 | 19.52 |
| Sep 30, 2024 | 27.49 |
| Jun 30, 2024 | 38.30 |
| Mar 31, 2024 | 48.33 |
| Dec 31, 2023 | 58.13 |
| Sep 30, 2023 | 61.73 |
| Jun 30, 2023 | 69.51 |
| Mar 31, 2023 | 89.38 |
| Dec 31, 2022 | 67.34 |
| Sep 30, 2022 | 67.12 |
| Jun 30, 2022 | 85.41 |
| Mar 31, 2022 | 93.33 |
| Dec 31, 2021 | 510.48 |
| Sep 30, 2021 | 283.16 |
API Access
Biomarin Pharmaceutical EV to EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=BMRN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebitda", "ticker": "BMRN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=BMRN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();